Trial Profile
A randomized, double-blind, phase III, comparative study of Cidecin (daptomycin) to Rocephin (ceftriaxone) in the treatment of moderate to severe community-acquired acute bacterial pneumonia due to S. [Streptococcus] pneumoniae
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Daptomycin (Primary) ; Ceftriaxone
- Indications Community-acquired pneumonia; Pneumococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors Cubist Pharmaceuticals
- 09 Oct 2007 New trial record.